Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Debt: 2014-2024

Historic Total Debt for ImmunityBio (IBRX) over the last 10 years, with Dec 2024 value amounting to $284.4 million.

  • ImmunityBio's Total Debt rose 15.53% to $316.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.1 million, marking a year-over-year increase of 15.53%. This contributed to the annual value of $284.4 million for FY2024, which is 83.00% up from last year.
  • Per ImmunityBio's latest filing, its Total Debt stood at $284.4 million for FY2024, which was up 83.00% from $155.4 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Total Debt peaked at $306.3 million during FY2021, and registered a low of $155.4 million during FY2023.
  • In the last 2 years, ImmunityBio's Total Debt had a median value of $219.9 million in 2023 and averaged $219.9 million.
  • Data for ImmunityBio's Total Debt shows a peak YoY spiked of 55,289.09% (in 2020) over the last 5 years.
  • Over the past 4 years, ImmunityBio's Total Debt (Yearly) stood at $269.2 million in 2020, then grew by 13.80% to $306.3 million in 2021, then reached $155.4 million in 2023, then spiked by 83.00% to $284.4 million in 2024.